FDA panel weighs allowing compounding of experimental peptides amid safety concerns
An FDA advisory committee will review seven experimental peptides to decide if they should be added to the 503A Bulks List, potentially letting state-licensed compounding pharmacies prepare them with prescriptions. Regulators say there is insufficient evidence on safety and effectiveness, raising concerns about long-term risks, while advocates argue a regulated pathway could reduce unsafe online sourcing. The decision is advisory, with final regulatory choices falling to the agency and potentially reshaping access to these non-FDA-approved peptides.